129 related articles for article (PubMed ID: 22995759)
1. A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide.
Wong SF; Gan HK; Cher L
J Clin Neurosci; 2012 Nov; 19(11):1501-5. PubMed ID: 22995759
[TBL] [Abstract][Full Text] [Related]
2. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.
Makino K; Nakamura H; Hide T; Kuratsu J
J Neurooncol; 2012 Jan; 106(1):155-60. PubMed ID: 21720808
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide for relapsed primary CNS lymphoma.
Osmani AH; Masood N
J Coll Physicians Surg Pak; 2012 Sep; 22(9):594-5. PubMed ID: 22980617
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Enting RH; Demopoulos A; DeAngelis LM; Abrey LE
Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145
[TBL] [Abstract][Full Text] [Related]
5. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Wong ET; Tishler R; Barron L; Wu JK
Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
[TBL] [Abstract][Full Text] [Related]
7. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
Salamoon M; Hussein T; Kenj M; Bachour M
Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450
[TBL] [Abstract][Full Text] [Related]
8. First-line therapy with temozolomide induces regression of primary CNS lymphoma.
Herrlinger U; Küker W; Platten M; Dichgans J; Weller M
Neurology; 2002 May; 58(10):1573-4. PubMed ID: 12034807
[No Abstract] [Full Text] [Related]
9. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.
Reni M; Mason W; Zaja F; Perry J; Franceschi E; Bernardi D; Dell'Oro S; Stelitano C; Candela M; Abbadessa A; Pace A; Bordonaro R; Latte G; Villa E; Ferreri AJ
Eur J Cancer; 2004 Jul; 40(11):1682-8. PubMed ID: 15251157
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.
Chamberlain MC
J Neurooncol; 2014 May; 118(1):155-62. PubMed ID: 24584709
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
Raizer JJ; Rademaker A; Evens AM; Rice L; Schwartz M; Chandler JP; Getch CC; Tellez C; Grimm SA
Cancer; 2012 Aug; 118(15):3743-8. PubMed ID: 22179954
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Plotkin SR; Betensky RA; Hochberg FH; Grossman SA; Lesser GJ; Nabors LB; Chon B; Batchelor TT
Clin Cancer Res; 2004 Sep; 10(17):5643-6. PubMed ID: 15355887
[TBL] [Abstract][Full Text] [Related]
16. Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.
Pitini V; Baldari S; Altavilla G; Arrigo C; Naro C; Perniciaro F
J Neurooncol; 2007 Jul; 83(3):291-3. PubMed ID: 17245621
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
Wang XX; Huang HQ; Bai B; Cai QQ; Cai QC; Gao Y; Xia YF; Xia ZJ; Jiang WQ
Leuk Lymphoma; 2014 Nov; 55(11):2497-501. PubMed ID: 24605911
[TBL] [Abstract][Full Text] [Related]
18. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
[TBL] [Abstract][Full Text] [Related]
19. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
Yamanaka R
Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.
Omuro AM; Taillandier L; Chinot O; Carnin C; Barrie M; Hoang-Xuan K
J Neurooncol; 2007 Nov; 85(2):207-11. PubMed ID: 17896079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
